Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial
Treatment with polyethylene glycol-modified interferon alfa-2a (peginterferon) alone produces significantly higher sustained antiviral responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterfer...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2003-07-01
|
Series: | Annals of Hepatology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268119321398 |
id |
doaj-7b8ef9abd4a6429394e1c4c88e5ab32f |
---|---|
record_format |
Article |
spelling |
doaj-7b8ef9abd4a6429394e1c4c88e5ab32f2021-06-08T04:36:50ZengElsevierAnnals of Hepatology1665-26812003-07-0123135139Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trialFrancisco Bosques-Padilla, MD0Rafael Trejo-Estrada, MD1Octaivio Campollo-Rivas, MD2Carlos Cortez-HernÁndez, MD3Margarita Dehesa-Violante, MD4Héctor Maldonado-Garza, MD5Raúl Pérez-Gómez, MD6Armando Cabrera-Valdespino, MD7Departamento de Medicina Interna. Servicio de Gastroenterología. Hospital Universitario Dr. José E. González UANL. Monterrey NL México; Address for correspondence:Departamento de Gastroenterología. Hospital de Especialidades Centro Medico Nacional Siglo XXI IMSS. México DFAntiguo Hospital Civil de Guadalajara. Centro Universitario Ciencias de la Salud (CUCS). Universidad de Guadalajara. Guadalajara Jalisco MéxicoDepartamento de Medicina Interna. Servicio de Gastroenterología. Hospital Universitario Dr. José E. González UANL. Monterrey NL MéxicoDepartamento de Medicina Interna. Servicio de Gastroenterología. Hospital Universitario Dr. José E. González UANL. Monterrey NL MéxicoDepartamento de Medicina Interna. Servicio de Gastroenterología. Hospital Universitario Dr. José E. González UANL. Monterrey NL MéxicoDepartamento de Medicina Interna. Servicio de Gastroenterología. Hospital Universitario Dr. José E. González UANL. Monterrey NL MéxicoDepartamento de Medicina Interna. Servicio de Gastroenterología. Hospital Universitario Dr. José E. González UANL. Monterrey NL MéxicoTreatment with polyethylene glycol-modified interferon alfa-2a (peginterferon) alone produces significantly higher sustained antiviral responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterferon alfa-2a plus rib-avirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C. Thirty-two patients were randomly assigned to treatment, and received at least one dose of medication consisting of 180 μ of peginterferon alfa-2a once weekly plus daily ribavirin (1,000 or 1,200 mg, depending on body weight) (n = 14), weekly peginterferon alfa-2a plus daily placebo (n = 6), or three million units of interferon alfa-2b thrice weekly plus daily ribavirin for 48 weeks (n = 12). More patients who received peginterferon alfa-2a plus ribavirin had a sustained virologic response (defined as the absence of detectable HCV RNA 24 weeks after cessation of therapy) than patients who received interferon alfa-2b plus ribavirin (7/14 vs. 4/12) or peginterferon alfa-2a plus placebo (0/6). The overall safety profiles of the three treatment regimens were similar. In conclusion, for patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferon alfa-2b plus ribavirin and produced significant improvements in the rate of sustained viral reduction compared with interferon alfa-2b plus ribavirin or peginterferon alfa-2a alone.http://www.sciencedirect.com/science/article/pii/S1665268119321398Chronic hepatitis CPeginterferon alfa-2a efficacyEarly prediction responseTreatment security. |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Francisco Bosques-Padilla, MD Rafael Trejo-Estrada, MD Octaivio Campollo-Rivas, MD Carlos Cortez-HernÁndez, MD Margarita Dehesa-Violante, MD Héctor Maldonado-Garza, MD Raúl Pérez-Gómez, MD Armando Cabrera-Valdespino, MD |
spellingShingle |
Francisco Bosques-Padilla, MD Rafael Trejo-Estrada, MD Octaivio Campollo-Rivas, MD Carlos Cortez-HernÁndez, MD Margarita Dehesa-Violante, MD Héctor Maldonado-Garza, MD Raúl Pérez-Gómez, MD Armando Cabrera-Valdespino, MD Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial Annals of Hepatology Chronic hepatitis C Peginterferon alfa-2a efficacy Early prediction response Treatment security. |
author_facet |
Francisco Bosques-Padilla, MD Rafael Trejo-Estrada, MD Octaivio Campollo-Rivas, MD Carlos Cortez-HernÁndez, MD Margarita Dehesa-Violante, MD Héctor Maldonado-Garza, MD Raúl Pérez-Gómez, MD Armando Cabrera-Valdespino, MD |
author_sort |
Francisco Bosques-Padilla, MD |
title |
Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial |
title_short |
Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial |
title_full |
Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial |
title_fullStr |
Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial |
title_full_unstemmed |
Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial |
title_sort |
peginterferon alfa-2a plus ribavirin for treating chronic hepatitis c virus infection: analysis of mexican patients included in a multicenter international clinical trial |
publisher |
Elsevier |
series |
Annals of Hepatology |
issn |
1665-2681 |
publishDate |
2003-07-01 |
description |
Treatment with polyethylene glycol-modified interferon alfa-2a (peginterferon) alone produces significantly higher sustained antiviral responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterferon alfa-2a plus rib-avirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C. Thirty-two patients were randomly assigned to treatment, and received at least one dose of medication consisting of 180 μ of peginterferon alfa-2a once weekly plus daily ribavirin (1,000 or 1,200 mg, depending on body weight) (n = 14), weekly peginterferon alfa-2a plus daily placebo (n = 6), or three million units of interferon alfa-2b thrice weekly plus daily ribavirin for 48 weeks (n = 12). More patients who received peginterferon alfa-2a plus ribavirin had a sustained virologic response (defined as the absence of detectable HCV RNA 24 weeks after cessation of therapy) than patients who received interferon alfa-2b plus ribavirin (7/14 vs. 4/12) or peginterferon alfa-2a plus placebo (0/6). The overall safety profiles of the three treatment regimens were similar. In conclusion, for patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferon alfa-2b plus ribavirin and produced significant improvements in the rate of sustained viral reduction compared with interferon alfa-2b plus ribavirin or peginterferon alfa-2a alone. |
topic |
Chronic hepatitis C Peginterferon alfa-2a efficacy Early prediction response Treatment security. |
url |
http://www.sciencedirect.com/science/article/pii/S1665268119321398 |
work_keys_str_mv |
AT franciscobosquespadillamd peginterferonalfa2aplusribavirinfortreatingchronichepatitiscvirusinfectionanalysisofmexicanpatientsincludedinamulticenterinternationalclinicaltrial AT rafaeltrejoestradamd peginterferonalfa2aplusribavirinfortreatingchronichepatitiscvirusinfectionanalysisofmexicanpatientsincludedinamulticenterinternationalclinicaltrial AT octaiviocampollorivasmd peginterferonalfa2aplusribavirinfortreatingchronichepatitiscvirusinfectionanalysisofmexicanpatientsincludedinamulticenterinternationalclinicaltrial AT carloscortezhernandezmd peginterferonalfa2aplusribavirinfortreatingchronichepatitiscvirusinfectionanalysisofmexicanpatientsincludedinamulticenterinternationalclinicaltrial AT margaritadehesaviolantemd peginterferonalfa2aplusribavirinfortreatingchronichepatitiscvirusinfectionanalysisofmexicanpatientsincludedinamulticenterinternationalclinicaltrial AT hectormaldonadogarzamd peginterferonalfa2aplusribavirinfortreatingchronichepatitiscvirusinfectionanalysisofmexicanpatientsincludedinamulticenterinternationalclinicaltrial AT raulperezgomezmd peginterferonalfa2aplusribavirinfortreatingchronichepatitiscvirusinfectionanalysisofmexicanpatientsincludedinamulticenterinternationalclinicaltrial AT armandocabreravaldespinomd peginterferonalfa2aplusribavirinfortreatingchronichepatitiscvirusinfectionanalysisofmexicanpatientsincludedinamulticenterinternationalclinicaltrial |
_version_ |
1721390822383943680 |